Swiss contract manufacturer Lonza and NeuroSense Therapeutics have partnered to detect exosome-based biomarkers to bolster diagnostics and treatments for neurodegenerative diseases, particularly amyotrophic lateral sclerosis (ALS).

The partnership will focus on evaluating biological changes in individuals with the conditions.

NeuroSense will benefit from Lonza’s expertise and capabilities in extracellular vesicles.

The collaboration will enable NeuroSense to access these services on an on-demand basis, without the need for further commitments.

NeuroSense will apply its broad experience with biomarkers in the field of neurodegenerative diseases to the partnership.

Lonza will develop, optimise and qualify a method for measuring biomarkers from neuron-derived exosomes.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

This method will be integrated into the development of NeuroSense’s prime candidate for ALS treatment, PrimeC.

NeuroSense recently announced positive top-line data from the Phase IIb PARADIGM clinical trial’s six-month double-blind segment, evaluating PrimeC in individuals with ALS.

The results indicated a statistically significant reduction in disease progression in the per-protocol population treated with PrimeC versus placebo.

NeuroSense CEO Alon Ben-Noon stated: “We believe this collaboration could be a game-changer for the ALS and neurodegeneration field, as findings in such biomarkers may advance early diagnosis and treatment, as well as expedite the regulatory pathway for new treatments for the millions of people who suffer from neurodegenerative diseases.

“Collaborating with Lonza enables us to tap into some of the world’s top experts in exosome-based therapies research to develop another important measure of PrimeC’s efficacy.”

The latest development comes after Lonza and Acumen Pharmaceuticals entered a strategic partnership to further the development of sabirnetug (ACU193), a potential treatment for Alzheimer’s disease.